

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

[A549/CDDP](#)

RRID:CVCL_C5RT

Type: Cell Line

Proper Citation

RRID:CVCL_C5RT

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_C5RT

Proper Citation: RRID:CVCL_C5RT

Description: Cell line A549/CDDP is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:20716419](#)

Comments: Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: A549/CDDP

Synonyms: A549/cDDP

Cross References: ChEMBL-Cells:ChEMBL4483129, ChEMBL-Targets:ChEMBL4483225, Wikidata:Q116048462

ID: CVCL_C5RT

Hierarchy: cvcl_0023

Record Creation Time: 20221216T070202+0000

Record Last Update: 20260905T183042+0000

Ratings and Alerts

No rating or validation information has been found for A549/CDDP.

No alerts have been found for A549/CDDP.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Liang B, et al. (2023) Novel Indole-Containing Hybrids Derived from Millepachine: Synthesis, Biological Evaluation and Antitumor Mechanism Study. *Molecules* (Basel, Switzerland), 28(3).

Chen TY, et al. (2022) SOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signaling. *Medical oncology* (Northwood, London, England), 39(3), 36.

Sun Y, et al. (2022) Ring finger protein 6 enhances chemo-resistance by transcriptionally activating proliferating cell nuclear antigen expression and attenuating DNA damage in lung adenocarcinoma. *Cancer letters*, 534, 215609.

Wang Y, et al. (2022) CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC). *Bioengineered*, 13(2), 3651.

Han B, et al. (2022) Exogenous proline enhances susceptibility of NSCLC to cisplatin via metabolic reprogramming and PLK1-mediated cell cycle arrest. *Frontiers in pharmacology*, 13, 942261.

Liu M, et al. (2021) PD-0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance. *Thoracic cancer*, 12(6), 924.

Sun Y, et al. (2021) ent-Kaurane diterpenoids induce apoptosis and ferroptosis through targeting redox resetting to overcome cisplatin resistance. *Redox biology*, 43, 101977.

He B, et al. (2021) miR-383 increases the cisplatin sensitivity of lung adenocarcinoma cells through inhibition of the RBM24-mediated NF- κ B signaling pathway. *International journal of oncology*, 59(5).

Yu H, et al. (2021) FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule-stabilizing effect. *Cancer science*, 112(11), 4655.

Statello L, et al. (2021) The DNA damage inducible lncRNA SCAT7 regulates genomic integrity and topoisomerase 1 turnover in lung adenocarcinoma. *NAR cancer*, 3(1), zcab002.

Liu Z, et al. (2020) Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance. *European journal of medicinal chemistry*, 194, 112269.

Wang W, et al. (2020) Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. *Molecular cancer*, 19(1), 134.

Cao W, et al. (2020) Gemcitabine inhibits cisplatin resistance in cisplatin-resistant A549 cells by upregulating trx-interacting protein and inducing cell cycle arrest. *Biochemical and biophysical research communications*, 524(3), 549.

Wang H, et al. (2020) Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. *Journal of experimental & clinical cancer research : CR*, 39(1), 29.

Wang X, et al. (2019) Retracted Article: Long noncoding RNA ANRIL knockdown increases sensitivity of non-small cell lung cancer to cisplatin by regulating the miR-656-3p/SOX4 axis. *RSC advances*, 9(66), 38735.

Zhang L, et al. (2019) miR-134-5p Promotes Stage I Lung Adenocarcinoma Metastasis and Chemoresistance by Targeting DAB2. *Molecular therapy. Nucleic acids*, 18, 627.

Sun Y, et al. (2019) Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer. *Cell death & disease*, 10(6), 400.

Wang N, et al. (2018) Negative Regulation of PTEN by MicroRNA-221 and Its Association with Drug Resistance and Cellular Senescence in Lung Cancer Cells. *BioMed research international*, 2018, 7908950.

Li L, et al. (2018) Long non-coding RNA CASC2 enhanced cisplatin-induced viability inhibition of non-small cell lung cancer cells by regulating the PTEN/PI3K/Akt pathway through down-regulation of miR-18a and miR-21. *RSC advances*, 8(29), 15923.

Song J, et al. (2017) Reversal of multidrug resistance in human lung cancer cells by delivery of 3-octadecylcarbamoyleacrylic acid-cisplatin-based liposomes. *Drug design, development and therapy*, 11, 441.